LAS VEGAS, Nevada — An oral Janus kinase 1 (JAK1) inhibitor upadacitinib (Rinvoq, AbbVie) showed…
View More Upadacitinib Shows Potential for Ulcerative ColitisHome »
Home »
LAS VEGAS, Nevada — An oral Janus kinase 1 (JAK1) inhibitor upadacitinib (Rinvoq, AbbVie) showed…
View More Upadacitinib Shows Potential for Ulcerative Colitis